Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial

Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders

(2021) Sébastien Delhaye et al.   MOLECULAR PSYCHIATRY

Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial

(2021) Mostafa Farajollahi-Moghadam et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder

(2021) Mahmoud S. Abdallah et al.   CNS Neuroscience & Therapeutics

Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial

(2021) Seyyede-Ozra Yasrebi et al.   JOURNAL OF PSYCHOSOMATIC RESEARCH

Insights into the potential antidepressant mechanisms of cilostazol in chronically restraint rats

(2018) Sally A. Abuelezz et al.   BEHAVIOURAL PHARMACOLOGY

The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial

(2018) Sahar Mohamed El-Haggar et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study

(2017) Farzin Rezaei et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews

(2017) Gerald Gartlehner et al.   BMJ Open

Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction

(2016) Nozomi Hishikawa et al.   Geriatrics & Gerontology International

Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder

(2015) Rita Haapakoski et al.   BRAIN BEHAVIOR AND IMMUNITY

PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

(2015) Atefeh Zeinoddini et al.   DEPRESSION AND ANXIETY

Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke

(2015) Yu Ri Kim et al.   PSYCHOPHARMACOLOGY

Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: Involvement of antioxidant and anti-apoptotic mechanisms

(2014) Lianshu Ding et al.   BEHAVIOURAL BRAIN RESEARCH

Beneficial effect of cilostazol-mediated neuronal repair following trimethyltin-induced neuronal loss in the dentate gyrus

(2014) Masanori Yoneyama et al.   JOURNAL OF NEUROSCIENCE RESEARCH

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients

(2013) Nazila Shahmansouri et al.   JOURNAL OF AFFECTIVE DISORDERS

Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis

(2013) Akihiko Taguchi et al.   Psychogeriatrics

Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010

(2013) Alize J. Ferrari et al.   PLOS MEDICINE

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

(2012) Hirofumi Sakurai et al.   Geriatrics & Gerontology International

Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder

(2012) Danial Khajavi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Effects of Add-On Cilostazol on Cognition in Patients With Schizophrenia

(2011) Yukihiko Shirayama et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial

(2010) Shahin Akhondzadeh et al.   PSYCHOPHARMACOLOGY

Stroke Prevention by Cilostazol in Patients with Atherothrombosis: Meta-analysis of Placebo-controlled Randomized Trials

(2009) Shinichiro Uchiyama et al.   Journal of Stroke & Cerebrovascular Diseases

Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus

(2009) Juan Zhao et al.   NEUROPHARMACOLOGY

Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise

(2008) Catharine H. Duman et al.   BEHAVIOURAL BRAIN RESEARCH

Novel Augmentation Therapy with Cilostazol for the Geriatric Major Depressive Disorder Patient with Deep White Matter Hyperintensities on T2-Weighted Brain MRI: A Case Report

(2008) K. Takahashi et al.   PHARMACOPSYCHIATRY

Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial

(2007) Shahrokh Amiri et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY